Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer JAMA Dermatology

TAKE-HOME MESSAGE

• The authors conducted a systematic review to determine the pooled relative risk (RR) estimates for overall cancer risk and specific cancer types in patients using topical calcineurin inhibitors (TCIs). There was no association between TCI use and overall cancer risk compared with nonactive comparators. There was also no significant association between TCI use and skin cancers, including melanomas and keratinocyte carcinomas. There was an increased risk of lymphoma noted with TCI use compared with nonactive (RR, 1.86) and corticosteroid comparators (RR, 1.35).

• Although this meta-analysis identified an increased RR of lymphoma with TCI use, the authors suggest that this increment translates to a very small increase in the risk of lymphoma for each patient, as the absolute risk of lymphoma is low.

–  Alex Noble, MD

Abstract

IMPORTANCE

Topical calcineurin inhibitors (TCIs) are commonly used as second-line treatment for atopic dermatitis. In 2006, the US Food and Drug Administration issued a black box warning against TCI use, citing data from case reports and animal studies indicating a potential risk of cancer.

OBJECTIVE

To evaluate the association between TCI use and risk of malignant neoplasms compared with nonactive and active comparator groups.

DATA SOURCES

Electronic searches were conducted in MEDLINE via Ovid, Embase via Ovid, and Web of Science from database inception to August 21, 2020.

STUDY SELECTION

Observational studies investigating the association between treatment with TCIs (ie, tacrolimus and pimecrolimus) and the development of cancer with nonactive or active comparators were included. The population of interest was not limited to any specific disease state, age, or sex. All articles were assessed independently and in duplicate by 2 reviewers. Risk of bias was assessed using the Newcastle-Ottawa scale. Of 2464 nonduplicate records retrieved from the search, 11 studies met the inclusion criteria.

DATA EXTRACTION AND SYNTHESIS

Data extraction was conducted independently by 2 reviewers according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Random-effects meta-analyses were used to derive pooled relative risk (RR) estimates. Data were analyzed from July 25 to October 25, 2020.

MAIN OUTCOMES AND MEASURES

Risk of cancer overall and risk of specific cancer types (lymphoma, melanoma, and keratinocyte carcinoma).

RESULTS

Eight unique cohort studies (408 366 treated participants [55.1% female], 1 764 313 nonactive comparator controls, and 1 067 280 controls using topical corticosteroids) and 3 unique case-control studies (3898 cases [55.0% male] and 14 026 cancer-free controls [52.4% male]) were included. There was no association between TCI use and cancer overall compared with nonactive comparators (RR, 1.03; 95% CI, 0.92-1.16). Lymphoma risk was elevated with TCI use with both nonactive (RR, 1.86; 95% CI, 1.39-2.49) and topical corticosteroid comparators (RR, 1.35; 95% CI, 1.13-1.61). No significant association was found between TCI use and increased skin cancer (melanoma and keratinocyte carcinoma).

CONCLUSIONS AND RELEVANCE

The findings of this systematic review and meta-analysis suggest an association between TCI use and risk of lymphoma but not other cancers. Combined with the low absolute risk of lymphoma, the potential increased risk attributable to TCI use for any individual patient is likely very small.

JAMA Dermatology

Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma: A Systematic Review and Meta-Analysis

JAMA Dermatol 2021 Mar 31;[EPub Ahead of Print], M Lam, JW Zhu, M Tadrous, AM Drucker

Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.